Format

Send to

Choose Destination
J Infect Dis. 2016 Aug 15;214(4):607-11. doi: 10.1093/infdis/jiw204. Epub 2016 Jun 20.

Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals.

Author information

1
Division of Infectious Diseases, Department of Medicine, Stanford University, Palo Alto.
2
Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston.
3
Division of Infectious Diseases, Departments of Pediatrics and Medicine, Case Western Reserve University, Cleveland.
4
Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle.
5
Division of Infectious Diseases, Department of Medicine, Ohio State University, Columbus.
6
Division of Infectious Diseases, Department of Medicine, University of Colorado, Aurora.
7
Division of Infectious Diseases, Department of Medicine, Columbia University, New York, New York.
8
New England Research Institute, Watertown, Massachusetts.
9
Viiv Healthcare, Research Triangle, North Carolina.
10
Gilead Sciences, Foster City, California.
11
Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University, Baltimore, Maryland.

Abstract

We compared adjusted bone mineral density (BMD) changes between human immunodeficiency virus (HIV)-infected individuals during the first approximately 7.5 years after antiretroviral therapy (ART) initiation and HIV-uninfected controls. HIV-infected individuals (n = 97) had significantly greater adjusted BMD decline than controls (n = 614) during the first 96 weeks of ART. Subsequently, the rate of BMD decline slowed in HIV-infected individuals but remained greater than the rate of decline in HIV-uninfected individuals at the lumbar spine but not at the hip. In HIV-infected individuals after 96 weeks, no HIV- or treatment-related characteristic was associated with BMD loss, but lower lean body mass was associated with greater BMD loss at both lumbar spine and hip.

KEYWORDS:

HIV infections, drug therapy/virology; anti-HIV agents, administration and dosage, adverse effects; bone density

PMID:
27330053
PMCID:
PMC4957444
DOI:
10.1093/infdis/jiw204
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center